Status:
COMPLETED
MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Diabetes Mellitus, Non-Insulin-Dependent
Eligibility:
All Genders
20-64 years
Phase:
PHASE1
Brief Summary
A single rising dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-1006 in Japanese participants with Type 2 Diabetes Mellitus (T2DM). The primary hypothesis of...
Eligibility Criteria
Inclusion
- Japanese male or female between 20 to 64 years of age
- Diagnosis of type 2 diabetes
- Patient is being treated with diet and exercise alone or single oral anti-hyperglycemic agent
Exclusion
- Subject has a history of type 1 diabetes mellitus
- Subject has a clinical diagnosis of glaucoma
- Subject has donated blood or participated in another clinical study in the past 12 weeks
- Subject is a regular user of any illicit drugs or has a history of drug, including alcohol, abuse in the past 6 months
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00791661
Start Date
November 1 2008
End Date
March 1 2009
Last Update
January 7 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.